Definition and characteristics of SMZL

The splenic marginal zone lymphoma (SMZL) belongs to the group of marginal zone lymphomas and is a rare mature B-cell neoplasm with indolent clinical course. The annual incidence is 0.13/100,000 persons (Liu et al. 2013). The disease occurs median in the 6th decade of life and manifests itself in the spleen with frequent involvement of bone marrow and peripheral blood. The splenic marginal zone lymphoma is formed by B cells from the marginal zone of the white splenic pulp (Swerdlow et al. 2017).

The aetiology of the splenic marginal zone lymphoma is not clear, but immunological stimulation seems to play a role besides acquired pathogenic mutations in oncogenes and tumor suppressor genes. Epidemiological studies also point to a connection to viral infections with human herpes virus 8 and hepatitis C virus (HCV) (Benavente et al. 2011, Hermine et al. 2002).

Classification of splenic marginal zone lymphoma

The group of marginal zone lymphomas accounts for up to 9% of non-Hodgkin's lymphomas (The non-Hodgkin's lymphoma classification project 1997). Based on the localization of the primary tumor, the WHO classification (2017) distinguishes three entities:

  • splenic marginal zone lymphoma (SMZL)
  • the extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)
  • nodal marginal zone lymphoma (NMZL) and the subtype of paediatric nodal marginal zone lymphoma

All three entities have the indolent course and the associated favorable prognosis in common.

SMZL - Diagnostics

Cytomorphology

The cytomorphology and histology of blood, bone marrow and lymph nodes is a guiding principle in the diagnostics of the various lymphoma entities for the control of the downstream diagnostics. On the one hand, the assessment of the bone marrow smear allows a first important statement to be made as to whether lymphoma circulation or lymphoma infiltration exists or is possible. Cytomorphology and histology are also useful for assessing the degree of lymphocyte maturity.

Cytomorphologically, lymphatic cells with short, polar arranged villi, plasmocytoid lymphatic cells and inconspicuous lymphocytes can be detected in peripheral blood smears. Morphological differentiation from other lymphoma entities is usually not easy (Haferlach 2020).

Immunophenotyping

Immunophenotyping in lymphomas allows to clearly determine the line affiliation to the T- or B-line. Furthermore, multiparametric flow cytometry is often indispensable to distinguish a reactive alteration from a lymphoid neoplasm, e.g. in EBV infections.

The neoplastic cells express the B-cell antigens CD19, CD20, CD22, CD79a and CD79b. Frequently there is an expression of membrane-bound immunoglobulin (mostly IgM, more rarely IgD) and FMC7. Usually CD5, CD10 and CD103 are not expressed. In rare cases, however, an expression of CD5 may occur, which is not associated with an altered prognosis (Baseggio et al. 2010). Since CD5 is an important marker to differentiate splenic marginal zone lymphoma from other lymphoid entities such as chronic lymphocytic leukemia or mantle cell lymphoma, it must also be assessed by morphological and genetic parameters. The antigens CD11c, CD23, CD25, CD43 and cyclin D1 can be variably expressed. In contrast to mantle cell lymphoma, cyclin D1 is only weakly expressed in splenic marginal zone lymphoma and can serve for differentiation (Arcaini et al. 2016, Piris et al. 2017).

Table 1: Immunophenotyping of splenic marginal zone lymphoma

Marker

Findings

CD19

+

CD20

+

CD22

+

CD79a

+

CD79b

+

FMC7

+

sIgM

+

CD10

-

CD103

-

CD5

+/-

CD11c

+/-

CD23

+/-

CD43

+/-

CD25

+/-

sIgD

+/-

Cyclin D1

+/-

Chromosome analysis

Up to 80% of patients with splenic marginal zone lymphoma have an aberrant karyotype (Zinzani 2012), with half of these patients having a complex aberrant karyotype (Salido et al. 2010). Various numerical and structural chromosomal abnormalities are found, none of which is specific to the SMZL.

The most common chromosomal alteration in splenic marginal zone lymphoma is 7q deletion, which is present in 39% of cases with aberrant karyotype and only rarely in other mature B cell neoplasm. In addition to the 7q deletion, trisomy 3 or a gain of 3q is observed in about 25% of cases. Further abnormalities are gains of 1q, 8q, 12(q) or 18 and/or losses of 1p, 6q, 8p or 13q. In about 12% of the cases a translocation involving the ICH locus (14q32) is present (Salido et al. 2010).

In very rare cases of splenic marginal zone lymphoma, the translocation t(2;7)(p12;q21); CDK6/IGK is present, which activates the CDK6 gene (Brito-Babapulle et al. 2002).

Cytogenetic abnormalities in splenic marginal zone lymphoma

Gains:
1q, 3(q), 8q, 12(q), 18

Losses:
1p, 6q, 7q, 8p, 13q

Balanced translocations:
t(14)(q32)
t(2;7)(p12;q21)/CDK6-IGK

FISH

Since splenic marginal zone lymphoma is characterized precisely by the absence of characteristic translocations, as is the case with follicular lymphoma (t(14;18); IGH-BCL2), mantle cell lymphoma (t(11;14); IGH-CCND1) and MALT lymphoma (t(11; 18); BIRC3/MALT1, t(14;18); IGH/MALT1 or t(1;14); IGH/BCL10), chromosome analysis as well as fluorescence in situ hybridization can significantly help to differentiate the presence of phenotypically similar entities of lymphomas. The presence of a 7q deletion may also indicate the presence of splenic marginal zone lymphoma.

Molecular genetics

In a splenic marginal zone lymphoma, the most frequently mutated genes are KLF2 (21%), NOTCH2 (20%), TP53 (15%) and IGLL5 (14%). Mutations in the three gene pairs KLF2 and IGLL5, TP53 and NOTCH2, and TP53 and KLF2 rarely occur together, indicating the possible presence of genetic subtypes of the SMZL (Oquendo et al. 2019). Especially in patients with splenic marginal zone lymphoma mutations of the NFkB signaling pathway occur frequently. Besides the transcription factor KLF2, other recurrently mutated genes of the NFkB signaling pathway are: TNFAIP3 (13%), MYD88 (8%), TRAF3 (8%), CARD11 (5%), IKBKB (4%) and BIRC3 (4%) (Oquendo et al. 2019, Parry et al. 2015, Clipson et al. 2015). Furthermore, about 30% of patients show rearrangements of the variable region (V) of the heavy chain (H) of immunoglobulins (IG) affecting the IGHV1-2*04 allele. Rarely, rearrangements of the alleles IGHV4-34 (~12%) and IGHV3-23 (~9%) are present (Salido et al. 2010, Bikos et al. 2010).

SMZL: Prognosis

The splenic marginal zone lymphoma is an indolent disease. The prognosis is usually very good and the median survival is 10 years. However, in 5-10% of the patients a transformation into a large B-cell lymphoma occurs, especially into a diffuse large B-cell lymphoma (Xing et al. 2015). The prognosis for patients with transformed SMZL is adverse (Florindez et al. 2019).

In splenic marginal zone lymphoma, a prognostic score has not yet been established. The splenic marginal zone lymphoma study group is striving for risk stratification, and its prognostic index takes the following parameters into account: haemoglobin, platelet count, lactate dehydrogenase, extrahilar lymphadenopathy (Kalpadakis et al. 2014) The Intergruppo Italiano Linformi Index (IIL) also includes the clinical parameters of haemoglobin and lactate dehydrogenase, and the IIL also includes serum albumin (Arcaini et al. 2006). Mutations of the TP53 gene are associated with a worse prognosis and patients with mutations of NOTCH2 and KLF2 have been observed to require earlier treatment (Parry et al. 2015).

Splenic marginal zone lymphoma - Recommendation

According to the current guideline of the "European Society for Medical Oncology" (ESMO) on marginal zone lymphoma, the diagnosis of splenic marginal zone lymphoma requires besides the collection of clinical and laboratory parameters a cytomorphological and immunophenotypical analysis of peripheral blood and bone marrow aspirate as well as a histological and immunohistochemical examination of the bone marrow. In a small percentage of cases, splenectomy is necessary for the diagnosis or exclusion of a splenic diffuse small cell B-cell lymphoma of the red pulp (SDRPL) (Zucca et al. 2020).

Therapy is usually initiated if progressive or symptomatic splenomegaly is present and/or any progressive cytopenia is detectable (haemoglobin <10 g/dl, platelets <80,000/µl, neutrophils <1000/µl) (Zucca et al. 2020). The assessment of the therapy response requires, like the diagnosis, the interaction of methods of cytomorphology, immunophenotyping as well as histology and immunohistochemistry. Thus, in addition to the clinical parameter of spleen size, hematological recovery, the proportion of circulating clonal cells in the blood and the extent of bone marrow infiltration are assessed (Zucca et al. 2020).

References

Arcaini L et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006;107(12):4643–4649.

Arcaini L et al. Splenic marginal zone lymphoma: from genetics to management. Blood 2016;127(17):2072–2081.

Baseggio L et al. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases. Haematologica 2010:95(4):604–612.

Benavente Y et al. Antibodies against lytic and latent Kaposi's sarcoma-associated herpes virus antigens and lymphoma in the European EpiLymph case-control study. British Journal of Cancer 2011;105(11):1768–1771.

Bikos V et al. Over 30% of Patients with Splenic Marginal Zone Lymphoma Express Distinctive Antigen Receptors Utilizing a Single Immunoglogulin Variable Gene. Implications for the Origin and Selection of the Neoplastic Cells. Blood 2010;116(21):634.

Brito-Babapulle V et al. Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin's lymphoma with leukemia. Haematologica 2002;87(4):357–362.

Clipson A et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia 2015;29(5):1177–1185.

Florindez J et al. Splenic Marginal Zone Lymphoma. A U.S Population-Based Survival Analysis (1997-2016). Blood 2019;134(Supplement_1):4014.

Haferlach T. Hämatologische Erkrankungen. Springer Verlag 2020; 3. Auflage.

Hermine O et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347(2):89–94.

Kalpadakis C et al. Validation of the simplified prognostic score for splenic marginal zone lymphoma of the Splenic Marginal Zone Lymphoma Working Group. Leukemia & Lymphoma 2014;55(11):2640–2642.

Liu L et al. Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States. Leukemia & Lymphoma 2013;54(7):1380–1386.

Oquendo C et al. Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma. Scientific reports 2019;9(1):10444.

Parry M et al. Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing. Clinical Cancer Research 2015; 21(18):4174–4183.

Piris M et al. Splenic marginal zone lymphoma. Best Practice & Research: Clinical Haematology 2017;30(1-2):56–64.

Salido M et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood 2010;116(9):1479–1488.

Swerdlow SH et al. WHO classification of tumours of haematopoetic and lymphoid tissue. International Agency of Research on Cancer 2017; 4. überarbeitete Version.

The non-Hodgkin's lymphoma classification project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89(11):3909-3918.

Xing K et al. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. British Journal of Haematology 2015;169(4):520–527.

Zinzani P. The many faces of marginal zone lymphoma. Hematology. American Society of Hematology. Education Program 2012:426–432.

Zucca et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(1):17-29.